Proverum, Ltd. appears in FDA records at an address on Eden Quay, Dublin, Ireland, as the applicant for the ProVee System for BPH. The device is classified as a permanent or semi-permanent prostatic urethral stent, product code MER, device class 3, reviewed by the Gastroenterology, Urology advisory committee. The original application was filed April 2, 2025 and approved December 9, 2025, with two supplements approved in 2026. [3][7][4]
The approved device and its stated scope
The approved labeling describes the ProVee System for BPH as intended for treatment of obstructive lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with prostatic urethral lengths greater than or equal to 3.75 cm and prostatic volumes between 30 and 80 cc. The same indication language appears in the FDA approval record and in the instructions for use, which list catalogue number PV-002 and identify the device as prescription use only. [3][5]
The instructions for use reference a ProVee Video Processing Unit and state that it requires precautions for electromagnetic compatibility with other electrical medical devices. A patient information guide describes the ProVee Expander as MR Conditional based on non-clinical testing, with conditions attached. These documents identify system components beyond the stent itself. [5][10]
Submission history in the supplied filings
The original PMA, P250011, was received April 2, 2025 and approved December 9, 2025. The approval letter is addressed to ProVerum Ltd. at the Dublin address, attention Niamh Mahony, Senior Regulatory Director, and is signed by Sharon M. Andrews, Director of the Division of Reproductive, Gynecology, and Urology Devices. The letter records the filing date and a September 5, 2025 amendment. [7][3]
Supplement S006, a Special (Immediate Track) process change covering manufacturer, sterilizer, packager or supplier, was received August 25, 2026 and approved September 24, 2026; its approval order statement describes the addition of a step to the final assembly process. Supplement S005, a Real-Time Process supplement for a change in design, components, specifications or material, was received the same day and approved November 3, 2026, with an approval order statement citing changes to the OmniVision CMOS Camera Cube. Neither supplement carried the expedited review flag. [2][1]
What the collection counts represent
The supplied collection links three PMA records for this applicant, all under P250011 and all with an approved decision. The smaller record sample of three entries corresponds to the original approval and the two supplements described above; the sample decision counts show three approvals. These figures describe the supplied filings as of the snapshot date and are not measures of company sales, total portfolio or safety performance. [1][2][3]
No recall records appear in the supplied sample. The FDA post-approval studies database page included in the sources describes the agency's authority to require post-approval studies but does not establish whether any study applies to this device. Ownership, parent companies, brand relationships, commercial availability and customer relationships are not documented in the public information. [9][3]






